Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Remember Biology 101? I sure do. It was the first class I had in my first semester in college at the ripe age of 18. It started at 7:30 in the morning, whether or not I did, and was taught by one of ...
Latus Bio Inc. is developing a new gene therapy, LTS-101, for the treatment of neuronal ceroid lipofuscinosis type2 (CLN2), a form of Batten disease characterized by deficiency in the tripeptidyl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback